Valencia Technologies' mission is to improve the quality of life for individuals suffering from OAB and related conditions by providing effective and minimally invasive neuromodulation therapies. Their key objectives include:

• Developing and Commercializing Innovative Neuromodulation Devices: Creating cutting-edge technology to address unmet medical needs in urology.
• Providing Safe and Effective Therapies: Ensuring the safety and efficacy of their products through rigorous clinical trials and regulatory compliance.
• Improving Patient Outcomes: Enhancing the quality of life for patients by reducing OAB symptoms and improving urinary control.
• Expanding Access to Neuromodulation Therapies: Making their therapies accessible to a wider patient population.
• Advancing Research and Development: Continuously investing in research and development to improve their products and explore new applications of neuromodulation.

Core Competencies and Services:

• eCoin? Percutaneous Tibial Nerve Stimulation (PTNS) System:
  • Valencia Technologies' flagship product is the eCoin? PTNS System, a minimally invasive neuromodulation device for the treatment of OAB.
  • The eCoin? system delivers electrical stimulation to the tibial nerve, which is believed to modulate the neural pathways involved in bladder control.
  • The device is implanted subcutaneously in the lower leg during a simple outpatient procedure.
  • Patients receive periodic stimulation sessions using an external wearable device.
• Neuromodulation Technology:
  • Valencia Technologies has expertise in developing and applying neuromodulation technologies for urological applications.
  • They focus on developing minimally invasive and patient-friendly devices that deliver targeted electrical stimulation.
  • Their neuromodulation approach aims to restore normal bladder function by modulating neural pathways.
• Clinical Research and Development:
  • Valencia Technologies conducts rigorous clinical research to evaluate the safety and efficacy of their products.
  • They have completed clinical trials demonstrating the effectiveness of the eCoin? system in reducing OAB symptoms.
  • They continue to invest in research and development to improve their products and expand their applications.
• Regulatory Compliance:
  • Valencia Technologies adheres to strict regulatory standards to ensure the safety and quality of their products.
  • They have obtained regulatory approvals for the eCoin? system in the United States and other countries.
  • They maintain compliance with relevant regulations and guidelines.
• Medical Device Manufacturing:
  • Valencia Technologies manufactures their medical devices in compliance with good manufacturing practices (GMP).
  • They focus on quality control and assurance to ensure the reliability and consistency of their products.
• Physician Training and Support:
  • Valencia Technologies provides training and support to physicians on the use of the eCoin? system.
  • They offer educational resources and technical assistance to ensure that physicians can effectively implant and manage the device.
  • They support physicians to integrate eCoin? therapy into their practice.

Target Audience:

• Patients with Overactive Bladder (OAB):
  • Valencia Technologies targets patients who are experiencing symptoms of OAB, such as urinary urgency, frequency, and urge incontinence.
• Urologists and Healthcare Professionals:
  • They work with urologists and other healthcare professionals who treat patients with OAB and related conditions.
• Hospitals and Clinics:
  • Valencia Technologies provides their products to hospitals and clinics that offer urological services.

Value Proposition:

• Minimally Invasive Therapy: The eCoin? system offers a minimally invasive alternative to traditional OAB treatments.
• Improved Quality of Life: The therapy aims to reduce OAB symptoms and improve urinary control, enhancing patients' quality of life.
• Long-Term Efficacy: Clinical studies have demonstrated the long-term efficacy of the eCoin? system.
• Patient-Friendly Design: The device is designed to be patient-friendly and easy to use.
• Clinically Proven Technology: The eCoin? system is supported by robust clinical evidence.

Impact and Contributions:

• Improved OAB Management: Valencia Technologies' eCoin? system provides a valuable treatment option for patients with OAB.
• Reduced Burden of OAB: The therapy aims to reduce the burden of OAB on patients' daily lives.
• Advancement of Neuromodulation Therapies: Valencia Technologies contributes to the advancement of neuromodulation therapies for urological applications.
• Enhanced Patient Care: The company supports healthcare professionals in providing effective and patient-centered care.

Future Outlook:

Valencia Technologies is poised for continued growth and expansion in the neuromodulation market. The company is likely to focus on:

• Expanding Market Access: Increasing the availability of the eCoin? system to a wider patient population.
• Developing New Applications: Exploring new applications of their neuromodulation technology in other urological conditions.
• Enhancing Product Features: Continuously improving the features and performance of the eCoin? system.
• Strengthening Clinical Evidence: Conducting further clinical studies to support the long-term efficacy and safety of their products.
• Expanding International Presence: Expanding their presence in international markets.

Overall, Valencia Technologies Corporation is a medical technology company dedicated to improving the lives of individuals with OAB through innovative neuromodulation therapies. Their commitment to research, development, and patient care makes them a significant player in the field of urology.